Ashi Anand suggests a GST cut on farm equipment could boost India's rural economy. He believes large-scale tariffs on medicines are unlikely, despite US policy unpredictability. Investors should be selective in pharma, focusing on biosimilars and CRAMS. GLP therapies present a major opportunity as patents expire. CDMOs and branded generic players are well-positioned to capitalize on this trend.